Prediction of drug-related cardiac adverse effects in humans-B: Use of QSAR programs for early detection of drug-induced cardiac toxicities

被引:42
作者
Frid, Anna A. [2 ]
Matthews, Edwin J. [1 ]
机构
[1] US FDA, Ctr Food Safety & Appl Nutr, Off Food Addit Safety, College Pk, MD 20740 USA
[2] GlobalNet Serv, Rockville, MD 20852 USA
关键词
AERS; BioEpisteme (TM); Clinical indication; Drug-induced cardiac toxicity; Drug-related adverse effect; In silico; Leadscope FDA Model Applier; MC4PC; Mechanism of action; QSAR; Quantitative structure-activity relationship; SRS; Therapeutic target; URINARY-TRACT TOXICITIES; DISCRIMINATING STRUCTURAL FEATURES; DEVELOPMENTAL TOXICITY; IN-SILICO; HAZARD IDENTIFICATION; INDUCED HEPATOBILIARY; CARCINOGENICITY DATA; COMPREHENSIVE MODEL; GENETIC TOXICITY; BUILDING-BLOCKS;
D O I
10.1016/j.yrtph.2009.11.005
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
This report describes the use of three quantitative structure-activity relationship (QSAR) programs to predict drug-related cardiac adverse effects (AEs), BioEpisteme (TM), MC4PC, and Leadscope Predictive Data Miner. QSAR models were constructed for 9 cardiac AE clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia. conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes) and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders) The models were based on a database of post-marketing AEs linked to 1632 chemical structures, and identical training data sets were configured for three QSAR programs Model performance was optimized and shown to be affected by the ratio of the number of active to inactive drugs Results revealed that the three programs were complementary and predictive performances using any single positive, consensus two positives, or consensus three positives were as follows. respectively 70 7%, 91 7%, and 98 0% specificity, 74 7%, 47.2%, and 21.0% sensitivity: and 138 2, 206 3, and 144 2 chi(2) In addition, a prospective study using AE data from the U S Food and Drug Administration's (FDA's) MedWatch Program showed 82.4% specificity and 94.3% sensitivity. Furthermore, an external validation study of 18 drugs with serious cardiotoxicity not considered in the models had 88.9% sensitivity (C) Published by Elsevier Inc
引用
收藏
页码:276 / 289
页数:14
相关论文
共 43 条
[1]  
[Anonymous], 2007, COMPUTATIONAL TOXICO
[2]  
Aronov A.M., 2007, COMPUTATIONAL TOXICO, P353
[3]   Structure-activity relationship studies of chemical mutagens and carcinogens: Mechanistic investigations and prediction approaches [J].
Benigni, R .
CHEMICAL REVIEWS, 2005, 105 (05) :1767-1800
[4]   Toxicological and clinical computational analysis and the USFDA/CDER [J].
Benz, R. Daniel .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2007, 3 (01) :109-124
[5]   Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models [J].
Contrera, Joseph F. ;
Kruhlak, Naomi L. ;
Matthews, Edwin J. ;
Benz, R. Daniel .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2007, 49 (03) :172-182
[6]   DESCRIBING THE VALIDITY OF CARCINOGEN SCREENING-TESTS [J].
COOPER, JA ;
SARACCI, R ;
COLE, P .
BRITISH JOURNAL OF CANCER, 1979, 39 (01) :87-89
[7]   Finding discriminating structural features by reassembling common building blocks [J].
Cross, KP ;
Myatt, G ;
Yang, C ;
Fligner, MA ;
Verducci, JS ;
Blower, PE .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (22) :4770-4775
[8]   A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME [J].
CURRAN, ME ;
SPLAWSKI, I ;
TIMOTHY, KW ;
VINCENT, GM ;
GREEN, ED ;
KEATING, MT .
CELL, 1995, 80 (05) :795-803
[9]   Cytochrome P450 in silico: An integrative modeling approach [J].
de Graaf, C ;
Vermeulen, NPE ;
Feenstra, KA .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) :2725-2755
[10]   Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports [J].
Evans, SJW ;
Waller, PC ;
Davis, S .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2001, 10 (06) :483-486